Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes

What Was Tested

Researchers studied Insulin Aspart and NPH Insulin (isophane) in this randomized controlled trial publication.

To compare long-term glycemic control and safety of using insulin aspart (IAsp) with that of regular human insulin (HI).

Who Took Part

The abstract describes 882 subjects taking part.

By PubMed's age tags, the people studied were teenagers, adults, middle-aged adults and older adults, both men and women.

This was a multicenter randomized open-label 6-month study (882 subjects) with a 6-month extension period (714 subjects) that enrolled subjects with type 1 diabetes.

How the Study Was Run

The researchers set it up as a randomized, open-label and multicenter study.

The subjects were allocated by chance, so the Insulin Aspart group and the comparison group should start out alike.

Nothing was hidden in this open-label Insulin Aspart study: the subjects and staff both knew the treatment.

Running at several centres spread the Insulin Aspart study over different clinics and patient groups.

Glycemic control was assessed with HbA1c values and 8-point blood glucose profiles at 3-month intervals.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Diabetes Mellitus, Type 1, Food, Glycated Hemoglobin, Hypoglycemic Agents, Insulin and Insulin Aspart.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Insulin Aspart and NPH Insulin (isophane) in 882 subjects.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2000 (Diabetes care), a journal based in United States.

More context: the Insulin Aspart compound page and the NPH Insulin (isophane) compound page, all human trials.